Immunomodulatory and neuroprotective effects of inosine

Trends in Pharmacological Sciences

Volumn 25, Issue 3, 2004, Pages 152-157

  Haskó, György ^a,b   Sitkovsky, Michail V ^c   Szabó, Csaba ^d,e  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d INOTEK CORPORATION   (United States)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; IMMUNOMODULATING AGENT; INOSINE; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BRAIN ISCHEMIA; CELL ENERGY; CELL HYPOXIA; CHRONIC INFLAMMATION; DRUG EFFECT; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG SELECTIVITY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; GLIA CELL; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MAST CELL DEGRANULATION; MEDIATOR RELEASE; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TISSUE INJURY;

EID: 1342264245     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.01.006     Document Type: Review

References (65)

1. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
2. Fredholm B.B., et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:2001;527-552.
3. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920.
4. Haskó G., et al. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157:1996;4634-4640.
5. Szabó C., et al. Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. 125:1998;379-387.
6. 2a receptor-dependent and independent mechanisms. FASEB J. 14:2000;2065-2074.
7. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275:2000;4429-4434.
8. 3 receptors. Neuroscience. 114:2002;523-527.
9. 3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48:2003;240-247.
10. 3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur. J. Pharmacol. 466:2003;323-329.
11. Haskó G., et al. Adenosine: a potential mediator of immunosuppression in multiple organ failure. Curr. Opin. Pharmacol. 2:2002;440-444.
12. 2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem. Pharmacol. 65:2003;493-501.
13. 3 adenosine receptors and stimulates mast cell degranulation. J. Clin. Invest. 100:1997;2849-2857.
14. Haskó G., et al. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J. Immunol. 164:2000;1013-1019.
15. 3 receptors on mast cells. J. Clin. Invest. 105:2000;361-367.
16. 2α receptors inhibits mast cell degranulation and mast cell-dependent vasoconstriction. Microcirculation. 7:2000;129-135.
17. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol. Pharmacol. 59:2001;76-82.
18. Fredholm B.B., et al. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 61:2001;443-448.
19. 3 adenosine receptors for the protective effect of inosine in vivo. Blood. 102:2003;4472-4478.
20. Deussen A. Metabolic flux rates of adenosine in the heart. Naunyn Schmiedebergs Arch. Pharmacol. 362:2000;351-363.
21. Pastor-Anglada M., et al. Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Mol. Membr. Biol. 18:2001;81-85.
22. Aldrich M.B., et al. The importance of adenosine deaminase for lymphocyte development and function. Biochem. Biophys. Res. Commun. 272:2000;311-315.
23. 2a receptor ligand binding site. J. Neurochem. 63:1994;1477-1484.
24. Benyon R.C., et al. The effect of methyltransferase inhibitors on histamine release from human dispersed lung mast cells activated with anti-human IgE and calcium ionophore A23187. Biochem. Pharmacol. 33:1984;2881-2886.
25. 3 adenosine receptor. Circ. Res. 78:1996;627-634.
26. Marton A., et al. Anti-inflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro. Int. J. Mol. Med. 8:2001;617-621.
27. Ulevitch R.J. New therapeutic targets revealed through investigations of innate immunity. Crit. Care Med. 29:2001;S8-12.
28. Garcia Soriano F., et al. Inosine improves gut permeability and vascular reactivity in endotoxic shock. Crit. Care Med. 29:2001;703-708.
29. Liaudet L., et al. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann. Surg. 235:2002;568-578.
30. Deitch E.A. Animal models of sepsis and shock: a review and lessons learned. Shock. 9:1998;1-11.
31. Liaudet L., et al. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am. J. Respir. Crit. Care Med. 164:2001;1213-1220.
32. Lam-Tse W.K., et al. Animal models of endocrine/organ-specific autoimmune diseases: do they really help us to understand human autoimmunity? Springer Semin. Immunopathol. 24:2002;297-321.
33. Mabley J.G., et al. Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Mol. Med. 9:2003;96-104.
34. Mabley J.G., et al. Inosine reduces inflammation and improves survival in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284:2003;G138-G144.
35. Mabley, J.G. et al. Inosine protects against development of collagen-induced rheumatoid arthritis. J. Autoimmun. (in press).
36. Scott G.S., et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc. Natl. Acad. Sci. U. S. A. 99:2002;16303-16308.
37. Hooper D.C., et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2528-2533.
38. de Jong J.W., et al. Myocardial nucleoside and carbohydrate metabolism and hemodynamics during partial occlusion and reperfusion of pig coronary artery. J. Mol. Cell. Cardiol. 9:1977;297-312.
39. Fox A.C., et al. Release of nucleosides from canine and human hearts as an index of prior ischemia. Am. J. Cardiol. 43:1979;52-58.
40. Hale S.L., et al. Alterations in the distribution of high-energy phosphates during ischemia in a canine model of reperfusion-induced ventricular fibrillation. Am. Heart J. 110:1985;590-594.
41. Eklund T., et al. Interstitial lactate, inosine and hypoxanthine in rat kidney during normothermic ischaemia and recirculation. Acta Physiol. Scand. 143:1991;279-286.
42. Juhasz-Nagy A., Aviado D.M. Inosine as a cardiotonic agent that reverses adrenergic beta blockade. J. Pharmacol. Exp. Ther. 202:1977;683-695.
43. Czarnecki W., Herbaczynska-Cedro K. The influence of inosine on the size of myocardial ischaemia and myocardial metabolism in the pig. Clin. Physiol. 2:1982;189-197.
44. DeWitt D.F., et al. Nucleotide degradation and functional impairment during cardioplegia: amelioration by inosine. Circulation. 67:1983;171-178.
45. Aussedat J., et al. Adenine nucleotide synthesis from inosine during normoxia and after ischaemia in the isolated perfused rat heart. Can. J. Physiol. Pharmacol. 63:1985;1159-1164.
46. Hagberg H., et al. Blockade of N-methyl-D-aspartate-sensitive acidic amino acid receptors inhibits ischemia-induced accumulation of purine catabolites in the rat striatum. Neurosci. Lett. 68:1986;311-316.
47. Wakai A., et al. Inosine attenuates tourniquet-induced skeletal muscle reperfusion injury. J. Surg. Res. 99:2001;311-315.
48. Dowdall J.F., et al. Inosine modulates gut barrier dysfunction and end organ damage in a model of ischemia-reperfusion injury. J. Surg. Res. 108:2002;61-68.
49. Yao Y.M., et al. The potential etiologic role of tumor necrosis factor in mediating multiple organ dysfunction in rats following intestinal ischemia-reperfusion injury. Resuscitation. 29:1995;157-168.
50. Seekamp A., et al. Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am. J. Pathol. 143:1993;453-463.
51. Stone T.W. Purines and neuroprotection. Adv. Exp. Med. Biol. 513:2002;249-280.
52. Haun S.E., et al. Inosine mediates the protective effect of adenosine in rat astrocyte cultures subjected to combined glucose-oxygen deprivation. J. Neurochem. 67:1996;2051-2059.
53. Jurkowitz M.S., et al. Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation. J. Neurochem. 71:1998;535-548.
54. Litsky M.L., et al. Inosine and guanosine preserve neuronal and glial cell viability in mouse spinal cord cultures during chemical hypoxia. Brain Res. 821:1999;426-432.
55. Benowitz L.I., et al. Axon outgrowth is regulated by an intracellular purine-sensitive mechanism in retinal ganglion cells. J. Biol. Chem. 273:1998;29626-29634.
56. Petrausch B., et al. A purine-sensitive pathway regulates multiple genes involved in axon regeneration in goldfish retinal ganglion cells. J. Neurosci. 20:2000;8031-8041.
57. Benowitz L.I., et al. Inosine stimulates extensive axon collateral growth in the rat corticospinal tract after injury. Proc. Natl. Acad. Sci. U. S. A. 96:1999;13486-13490.
58. Chen P., et al. Inosine induces axonal rewiring and improves behavioral outcome after stroke. Proc. Natl. Acad. Sci. U. S. A. 99:2002;9031-9036.
59. Reid P.G., et al. Intravenous infusion of adenosine but not inosine stimulates respiration in man. Br. J. Clin. Pharmacol. 23:1987;331-338.
60. 2 peak. Med. Sci. Sports Exerc. 22:1990;517-522.
61. McNaughton L., et al. Inosine supplementation has no effect on aerobic or anaerobic cycling performance. Int. J. Sport Nutr. 9:1999;333-344.
62. Spitsin S., et al. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult. Scler. 7:2001;313-319.
63. Hooper D.C., et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 95:1998;675-680.
64. Virag L., Szabo C. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J. 15:2001;99-107.
65. Virag L., Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54:2002;375-429.